---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-002160"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T07:08:30.401316+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals secures $8.9M financing from Anson Funds to support NDA filings, operations into 2026

## Summary
- Issued $5.435M senior secured notes (net proceeds ~$5M) and warrants for 862,699 shares at $3.78 strike; registered direct offering of 1,215,278 shares at $2.88/share.
- Total gross proceeds of ~$8.9M from Anson Funds; notes carry 8% OID, 6% interest, 15-month maturity, convertible at $3.78/share subject to reset.
- Proceeds will fund NRX-100 and NRX-101 NDA filings, HOPE Therapeutics launch, and potential pipeline additions; expected to fund operations into 2026.
- Company believes combined with projected sales and non-dilutive funding it can reach profitability; includes waiver of certain investor rights through March 31, 2025.

## SEC filing metadata
- accession: 0001437749-25-002160
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/0001437749-25-002160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925002160/nrxp20250128_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-002160
- JSON: https://secwatch.observer/filing/0001437749-25-002160.json
- Plain text: https://secwatch.observer/filing/0001437749-25-002160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.